Congratulations to all of these IASLC Academy participants - early-career physicians interested in academic careers in thoracic oncology, partnered with expert mentors through the year. Looking forward to seeing all that you do!

FLAURA2 exploratory analysis discussion by Marina Garassino at #AACR24 :
🔺dynamic ctDNA analysis not useful for clinical decisions
🔹baseline detection of EGFRm is prognostic and may select for a higher degree of clinical benefit from Osi+CT
AACR

What is the role of the TME in lung cancer evolution? We are excited to share our new TRACERx paper “Spatial Architecture of Myeloid and T Cells Orchestrates Immune Evasion and Clinical Outcome in Lung Cancer” at #AACR24 , out in Cancer Discovery today rb.gy/q484j9 Tweetorial👇

Enlightening presentation on AI-based biomarkers in cancer histopathology at #AACR24 from Jakob Nikolas Kather
👉🏻Do not blindly trust AI!
AACR

Eortc time at ELCC24 ESMO - Eur. Oncology Mariana Brandao Mario Occhipinti Francesco Cortiula Lodovica Zullo Arianna Marinello, MD Rita Leporati Alessio Cortellini Giovanni Pastorino

🚨The future of #ThoracicOncology is in great hands!

My co-chair colleague Dr Christian Rolfo, myself, great faculty mentors, & #IASLC staff are honored to kick off the:

“2024 global IASLC #Academy .”

Welcome to an outstanding group of #EarlyCareer #Physicians & #Researchers .

Pleased to share our review on recent advances and future strategies in first-line treatment of ES-SCLC. Thanks to all co-authors and friends involved Rita Leporati, Brinda Gupta, Stephen V Liu, MD , Raffaele Califano authors.elsevier.com/c/1iWx63QE--Z7…

APOLLO 11 Project, Consortium in Advanced #Lung #Cancer Patients Treated With #Innovative #Therapies : Integration of Real-World Data and Translational Research - Clinical Lung Cancer using #ArtificialIntelligence to analyze the data. #datadriven #model clinical-lung-cancer.com/article/S1525-…

Evidence on immune predictors is fragmented, thus requiring caution. That said, this retrospective study highlights early modifications of lymphocyte counts on CDK4/6i-ET are associated w/ better PFS & OS in pts w/ met HR+/HER2− #breastcancer shorturl.at/zBGM8 Therapeutic Advances in Medical Oncology

Sincerely grateful to the #FONICAP Foundation and to Dr. Santo for believing in young thoracic oncologists and unwaveringly supporting #lungunits and projects aimed at enhancing patient care 🫁

fonicap.it

Roberto Ferrara Laura Mazzeo, MD

It was a great honor for me today to discuss the PEANUT trial update to #AIOM . Pembrolizumab + nab-paclitaxel confirmed a significant efficacy in #mUC over 4 years of mFUP.
‼️ORR 50.0%; DCR 75.8%
‼️mPFS 5.1 mo; mOS 11.0 mo
My thanks to the GU Oncology Team of Istituto Tumori

Can Bone Targeted Agents’ use enhance ICI efficacy in aNSCLC pts with bone mets?

➡️ Take a look to out study on Lung Cancer Journal showing a survival benefit upon concomitant #ICI and #denosumab administration in #aNSCLC pts with high bone tumor burden #HBTB

Roberto Ferrara

What a joy to have these Young & Early Career Investigators of the EORTC Lung Cancer Group 🫁coming from so many different countries to exchange knowledge, finally meet F2F and relax together during #ESMO24
Thanks to Anne-Marie Dingemans and the LCG Board for all of your support! 🙏

Transcriptomic analysis to better predict prognosis of epithelioid malignant #pleuralmesothelioma
Well done Mario Occhipinti
Istituto Tumori

❗️@LaClaudia83 presenting the results of the RELEVENT study at #ESMO2023

💭New treatment option for a rare disease as thymic carcinoma
ESMO - Eur. Oncology

The #ESMOPreceptorship on #Immuno -Oncology just wrapping up 🙌 A two-day educational event covering many subjects, from the essentials of tumour immunology to clinical application.
Upcoming courses: ow.ly/fZ6150PRvwt
Curioni_Oncology_MD Angela Lamarca Solange Peters David James Pinato 🇺🇦

Definitely more than colleagues! ❤️
#lungcancer
#cocktailwithscience

Giuseppe Lo Russo @LaClaudia83 arsela prelaj Marta Brambilla Mario Occhipinti Teresa Beninato Laura Mazzeo, MD Marina Garassino Roberto Ferrara giuseppe viscardi Rita Leporati

Looking forward to the IV edition of the most awaited #cocktailwithscience #lungcancer meeting in Milan
👉🏻 lungcancer-milan.com

Powered by Giuseppe Lo Russo and a stellar faculty